Property Name |
Property Value |
Unit |
Raw Value |
Raw Unit |
Annotation |
Factor |
Reference |
AUC |
572.0 |
mg.min/1.73m2 |
572.0 |
mg.min/1.73m2 |
PO, oral; |
|
DRUGBANK |
AUC |
1034.0 |
mg.min/1.73m2 |
1034.0 |
mg.min/1.73m2 |
PO, oral; |
|
DRUGBANK |
AUC |
2271.0 |
mg.min/1.73m2 |
2271.0 |
mg.min/1.73m2 |
|
|
DRUGBANK |
Bioavailability |
80.0 |
% |
80±11 |
% |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
C Max |
71.5 |
ng/ml |
62-81 |
ng/ml |
Oral single dose; adults; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
C Max |
218.5 |
ng/ml |
198-239 |
ng/ml |
Oral single dose; Active metabolite; adults; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
T Max |
2.0 |
h |
2 |
h |
PO, oral; |
|
DRUGBANK |
T Max |
6.3 |
h |
6-6.5 |
h |
PO, oral; extended release formulation; |
|
DRUGBANK |
T Max |
2.6 |
h |
2.1-3.1 |
h |
Oral single dose; adults; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
T Max |
1.9 |
h |
1.2-2.6 |
h |
Oral single dose; Active metabolite; adults; normal,healthy; |
|
The Pharmacological Basis of Therapeutics |
Clearance |
0.0660 |
L/h/kg |
0.066±0.12 |
L/h/kg |
Average clearance; intravenous infusion, IV in drop; |
|
DRUGBANK |
Clearance |
0.15 |
L/h/kg |
0.15 |
L/h/kg |
Average clearance; intravenous infusion, IV in drop; |
|
DRUGBANK |
Clearance |
0.22 |
L/h/kg |
3.6±0.8 |
ml/min/kg |
|
Hepatitis, Hep → ; |
The Pharmacological Basis of Therapeutics |
Clearance |
0.15 |
L/h/kg |
2.5 |
ml/min/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Volume of Distribution |
29.3 |
L |
29.3 |
L |
|
|
DRUGBANK |
Volume of Distribution |
44.2 |
L |
44.2 |
L |
|
|
DRUGBANK |
Volume of Distribution |
0.97 |
L/kg |
0.97±0.11 |
L/kg |
|
Hepatitis, Hep → ; |
The Pharmacological Basis of Therapeutics |
Volume of Distribution |
0.57 |
L/kg |
0.57 |
L/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Half-life |
2.0 |
h |
2 |
h |
immediate release formulation; extended release formulation; |
|
DRUGBANK |
Half-life |
2.0 |
h |
2 |
h |
immediate release formulation; extended release formulation; |
|
DRUGBANK |
Half-life |
3.6 |
h |
3.6±0.4 |
h |
|
Hepatitis, Hep → ;Somking → ; |
The Pharmacological Basis of Therapeutics |
Half-life |
2.9 |
h |
2.9 |
h |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Eliminate Route |
3.0 |
% |
3±2 |
% |
Urinary excretion; Unchanged drug; |
hyperthyroid, HTh → ; |
The Pharmacological Basis of Therapeutics |
Protein Binding |
50.0 |
% |
<50 |
% |
|
|
DRUGBANK |
Protein Binding |
75.0 |
% |
75±2 |
% |
|
|
The Pharmacological Basis of Therapeutics |